Sanofi Buys TargeGen, Biogen Idec Hires CEO, Orexigen Obesity Drug Shows Promise Against Diabetes, & More San Diego Life Sciences News

7/1/10Follow @bvbigelow

(Page 2 of 2)

debt, securities, and warrants or rights. The San Diego biotech, which got $5.7 million a couple of years ago, intends to raise another $1.9 million for developing small molecule drugs that block the production of complex carbohydrates known as glycans.

—The National Institute on Drug Abuse has awarded an innovation grant worth $350,000 over two years to San Diego’s Multimeric Biotherapeutics to develop a vaccine against nicotine, and eventually other drugs of abuse. Multimeric says vaccines against nicotine are designed to generate antibodies that sequester nicotine in the blood and prevent the molecules from crossing into the brain and re-enforcing the nicotine habit. The two-year-old biotech is developing proprietary methods for boosting highly targeted antibody responses.

—The World Economic Forum convened a one-day summit on mobile health at the Estancia La Jolla Hotel & Spa. Some 75 or so academic, policy, and business leaders from eight countries were invited to attend the conference, which focused on ways to resolve the tangle of regulatory and policy problems that threaten to thwart the advance of wireless health technologies.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.